Bone Marrow Derived Mononuclear Cells for Ischemic Cardiomyopathy

Inclusion Criteria: * chronic left ventricular dysfunction (ejection fraction \<35 %) in chronic ischemic heart disease and asynchronic contraction with indication for a biventricular stimulation (CRT, chronic resynchronization therapy), who do not have an improvement of \>15% of LVEF 3 months after CRT-device implantation * wall motion dysfunction of any territory * left bundle branch block * Patients were on individual optimal treatment for chronic ischemic heart disease with one or a combination of the following drug types: diuretics, ß-blockers, ACE-inhibitors, AT1 blockers and/or lipid lowering agents for at least 30 days before CRT Implantation Exclusion Criteria: * patients with left ventricular dysfunction due to other reasons than ischemic cardiomyopathy, e.g. hypertension, dilatative cardiomyopathy * with relevant valvular disease; * Aneurysma of the anterior myocardial wall or myocardial wall thickness of \< 5 mm, * with overt heart failure, other than ischemic cardiomyopathy, * with history of stroke and/or transient ischemic attack (TIA), * with history of thromboembolic event (e.g. phlebothrombosis, pulmonary embolism), bleeding disorders and known disease of the coagulation system; * with extensive deviations of baseline laboratory values and significant findings at physical examination which in the opinion of the investigator may worsen under treatment; * with severe systemic disease - (e.g. known or suspected anaphylaxia, intolerance against X-ray or contrast agent and, pre-malignant and malignant disease) * atrial fibrillation with average heart rate \>70 bpm * pregnant women and women of childbearing potential who have not had a negative pregnancy test within 48 hours before treatment; * with any disease or condition that seriously compromises the function of other body systems than the heart and/or might interfere with conduct of the study and interpretation of the results; * patients with a chronic or acute HIV-, HBV-, HCV-infection; * improvement of more than 15% of LVEF 3 months after CRT-device implantation * patients who have a ICD Implantation for secondary prophylactic indication. These patients show a history of resuscitation, VT or syncope. * patients who are currently participating in another investigational drug or device study